Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part I: overview and recommendations

T. Banaschewski, D. Coghill, P. Santosh, A. Zuddas, P. Asherson, J. Buitelaar, M. Danckaerts, M. Döpfner, S.V. Faraone, A. Rothenberger, J.A. Sergeant, H.C. Steinhausen, E.J.S. Sonuga-Barke, E. Taylor

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. © 2008 by Verlag Hans Huber, Hogrefe AG.
Original languageEnglish
Pages (from-to)81-94
JournalZeitschrift für Kinder und Jugendpsychiatrie und Psychotherapie
Volume36
Issue number2
DOIs
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part I: overview and recommendations'. Together they form a unique fingerprint.

Cite this